• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Final Overview of MDR HIV Treatment Landscape


Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.

Ryan Haumschild, PharmD, MS, MBA: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you. Dr Sension, what are your final thoughts for our viewers after this discussion?

Michael Sension, MD: Multidrug resistance is a very interesting discussion. Each person who’s facing multidrug-resistant virus in their body is different. Each person has to have a customized approach to successful management. There’s no treatment algorithm or formula for treating multidrug resistance, but it truly is the art of medicine interacting with real human life patient dynamics that will successfully lead to a positive outcome.

Ryan Haumschild, PharmD, MS, MBA: I love the individual view of treatment. You’ve definitely given us a lot to think about with that shared decision-making framework. Dr Lopes, [what are] your final thoughts for our audience?

Maria Lopes, MD, MS: It’s an exciting time as we have more treatment options for this very small population. We started with less than 1%, and now we have 3 treatment options. There’s still the backbone issue, so it’s incumbent to focus on shared decision-making but also support and adherence. It’s not about 1 drug, so how can we improve the value of these treatments and get successful outcomes?

Ryan Haumschild, PharmD, MS, MBA: [There are] lots of innovations in therapy, but [there’s] still more work to be done. Mr Driffin, I’ll give you the final thoughts.

Daniel Driffin, BS, MPH: The conversation must be centered on social determinants of health. We have to have those ongoing conversations to ensure that solutions are being provided. Solutions include support systems, housing, employment, and insurance access, but also to ensure that individuals living with HIV have a valuable role in being the healthiest they can be with their medical providers.

Ryan Haumschild, PharmD, MS, MBA: Thank you to my expert panel and our viewing audience. We hope you found this AJMC® Peer Exchange to be useful and informative.

Transcript edited for clarity.

Related Videos
Stephanie L. Graff, MD, an expert on breast cancer
B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS
A panel of 5 experts on Alzheimer disease
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
Related Content
© 2024 MJH Life Sciences
All rights reserved.